IMPORTANCE Approximately one-quarter of adnexal masses detected at ultrasonography are indeterminate for benignity or malignancy, posing a substantial clinical dilemma. OBJECTIVE To validate the accuracy of a 5-point Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) score for risk stratification of adnexal masses. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study was conducted between March 1, 2013, and March 31, 2016. Among patients undergoing expectant management, 2-year follow-up data were completed by March 31, 2018. A routine pelvic MRI was performed among consecutive patients referred to characterize a sonographically indeterminate adnexal mass according to routine diagnostic practice at 15 referral centers. The MRI score was prospectively applied by 2 onsite readers and by 1 reader masked to clinical and ultrasonographic data. Data analysis was conducted between April and November 2018. MAIN OUTCOMES AND MEASURES The primary end point was the joint analysis of true-negative and false-negative rates according to the MRI score compared with the reference standard (ie, histology or 2-year follow-up). RESULTS A total of 1340 women (mean [range] age, 49 [18-96] years) were enrolled. Of 1194 evaluable women, 1130 (94.6%) had a pelvic mass on MRI with a reference standard (surgery, 768 [67.9%]; 2-year follow-up, 362 [32.1%]). A total of 203 patients (18.0%) had at least 1 malignant adnexal or nonadnexal pelvic mass. No invasive cancer was assigned a score of 2. Positive likelihood ratios were 0.01 for score 2, 0.27 for score 3, 4.42 for score 4, and 38.81 for score 5. Area under the receiver operating characteristic curve was 0.961 (95% CI, 0.948-0.971) among experienced readers, with a sensitivity of 0.93 (95% CI, 0.89-0.96; 189 of 203 patients) and a specificity of 0.91 (95% CI, 0.89-0.93; 848 of 927 patients). There was good interrater agreement among both experienced and junior readers (κ = 0.784; 95% CI, 0.743-0824). Of 580 of 1130 women (51.3%) with a mass on MRI and no specific gynecological symptoms, 362 (62.4%) underwent surgery. Of them, 244 (67.4%) had benign lesions and a score of 3 or less. The MRI score correctly reclassified the mass origin as nonadnexal with a sensitivity of 0.99 (95% CI, 0.98-0.99; 1360 of 1372 patients) and a specificity of 0.78 (95% CI, 0.71-0.85; 102 of 130 patients). Resonance Imaging (O-RADS MRI) score accurate for stratifying the risk of malignancy of sonographically indeterminate adnexal masses? Findings In this multicenter cohort study that included 1340 women, the O-RADS MRI score had a sensitivity of 0.93 and a specificity of 0.91. Meaning Applying this score in clinical practice may allow a tailored, patientcentered approach for adnexal masses that are sonographically indeterminate, preventing unnecessary surgery, less extensive surgery, or fertility preservation when appropriate, while ensuring preoperative detection of lesions with a high likelihood of malignancy.
Introduction
Adnexal masses are common, resulting in a significant clinical workload related to diagnostic imaging, surgery, and pathology. 1, 2 Most adnexal masses are benign, and most masses can be accurately categorized as benign or malignant on ultrasonography. 3, 4 However, between 18% and 31% of adnexal masses remain indeterminate following ultrasonography using International Ovarian Tumor Analysis (IOTA) Simple Rules or other ultrasonography scoring systems. 3, 4 Moreover, this prevalence may be an underestimation, given that many studies only report the cases with available surgical reference standards. 4 There are very limited data on patients who undergo only imaging and clinical follow-up. In a prospective external validation of the IOTA Simple Rules 5 among 666 women, 362 women (54.4%) underwent surgery, 309 of whom (85.4%) had benign masses. The authors reported that, among 304 patients (45.6%) who underwent expectant management, 71 patients (23.4%) experienced disappearance of the mass, and 233 (76.6%) had a persistent mass on imaging follow-up that was considered benign after 1 year of follow-up.
Percutaneous biopsy of a suspicious adnexal mass is not advised because of the risk of potentially upstaging a confined early-stage ovarian cancer or because of the risk of sampling error, resulting in a missed cancer diagnosis. As a result, despite the low rate of malignant adnexal masses discovered at ultrasonography (ie, 8%-20%), 5,6 a significant number of women with sonographically indeterminate but benign adnexal masses undergo potentially unnecessary or inappropriately extensive surgical interventions. 7, 8 This increases the risk of loss of fertility as well as morbidity, as reported in the 2 largest ovarian cancer screening trials. 7, 8 Conversely, some women with an indeterminate adnexal mass undergo initial, limited, noncancer surgery and are found to have ovarian cancer, with a risk of suboptimal initial cytoreductive surgery and significantly poorer outcomes. 9 Thus, preoperative characterization and risk stratification of indeterminate adnexal masses are unmet clinical needs. A validated scoring system that standardizes imaging reports and categorizes the risk of malignant neoplasm in these women would be useful as a triage test to decide whether surgery is appropriate and, if so, the extent of surgery required. This could potentially reduce unnecessary or overextensive surgery. In the literature, various scoring systems have been developed based on clinical, biochemical (eg, cancer antigen 125 [CA 125] or human epididymis protein 4 [HE 4] levels), and ultrasonographic criteria. 10, 11 Nevertheless, a significant subgroup of adnexal masses remain indeterminate despite optimal sonographic risk assessment, hampering treatment planning. 12, 13 A magnetic resonance imaging (MRI) scoring system was developed in a retrospective single-center study 14 among a cohort of 497 patients with indeterminate adnexal masses at ultrasonography. This MRI-based score consisted of 5 categories according to the positive likelihood ratio for a malignant neoplasm. 14 The score was based on MRI features with high positive and high negative predictive values in distinguishing benign from malignant masses that were considered indeterminate on ultrasonography. However, the score warrants validation from a multicenter study among a large cohort of women. Therefore, the primary objective of this study was to test the score for risk stratification in women referred for an MRI of sonographically indeterminate adnexal masses in a large, prospective, multicenter clinical study. The findings provide the evidence to support the publication of the Ovarian-Adnexal Reporting Data System Magnetic (O-RADS) MRI score version 1.
group (eAppendix 1 in the Supplement). According to French regulations at the time of study initiation, the study was approved by the Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé. In addition, the protocol was approved by the ethics committee of each participating site. All participating women provided written informed consent. The study protocol appears in eAppendix 2 of the Supplement. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Study Population
Consecutive women older than 18 years who were referred to a study center for MRI to characterize a sonographically indeterminate adnexal mass were invited to participate. Exclusion criteria were pregnancy or any contraindication to MRI (eAppendix 3 in the Supplement).
MRI Acquisition and Analysis
Each patient underwent a routine pelvic MRI (1.5 T or 3 T), including morphological sequences (ie, T2-weighted; T1-weighted, with and without fat suppression; and T1-weighted after gadolinium injection) and functional sequences (ie, perfusion-weighted and diffusion-weighted sequences). If no adnexal mass was present on T2-wieghted and T1-weighted sequences, functional sequences and gadolinium injection were not mandatory (eAppendix 4 in the Supplement). Presence of ascites was noted. Up to 3 pelvic masses per patient were analyzed. All MRI readers were masked to the final outcome.
Reader Training
During study setup, a session of 30 anonymized MRI scans (acquired before the beginning of the study) were downloaded for a training session for all teams participating in the multicenter validation to learn how to apply the score. A standardized lexicon was used for interpretation. 14 
Reference Standard

Statistical Analysis
The study end point was the joint analysis of true-negative and false-negative rates according to the MRI score compared with the reference standard. The sample size was determined based on previous results 14 to ensure that this study would have power of at least 90% to show a difference in diagnostic odds ratio between a score of 2 and 3 and between a score of 4 and 5. A total sample size of 1340 patients would ensure a probability of at least 95% to obtain the required 569, 250, 52, and 51 patients with MRI scores of 2, 3, 4, and 5, respectively, 15 assuming that 6% of patients would have lesions classified as a score of 1 and 10% of patients would be lost to follow-up.
For statistical analysis, the MRI score was matched to the reference standard. These analyses used the prospective, experienced reader's rating.
Diagnostic accuracy was evaluated both at the patient level and at the lesion level in terms of positive likelihood ratios (PLRs) and negative likelihood ratios (NLRs) for malignant masses. In addition, sensitivities, specificities, positive predictive values (PPVs), and negative predictive values (NPVs) were computed for dichotomized scores (ie, score of 2 and 3 [benign] vs score of 4 and 5
[malignant], according to predefined cutoff at 3 for the score).
To evaluate interobserver agreement, we used receiver operating characteristic curve analysis and compared the area under receiver operating characteristic curves between experienced and junior readers. 16 We also computed weighted quadratic κ coefficients. 17 Patients lost to follow-up (130 [9.7%]), patients for whom MRI failed to be completed (9 [0.7%]), and patients who withdrew consent (7 [0.5%]) were excluded from analyses. Among patients who were lost to follow-up, subjective assessment by experienced readers was indeterminate, borderline, or invasive in 12 of 130 patients (9.2%).
Estimates are provided with their 95% CIs. A 2-tailed P < .05 was considered statistically significant. Statistical analyses were performed using MedCalc version 9.3.0.0 (MedCalc Software) and R version 3.5.0 (R Project for Statistical Computing).
Results
Patients and Lesions
Overall, 1340 patients were enrolled in the study. The mean (range) age was 49 (18-96) years. The final, evaluable population included 1194 patients (89.1%), after 130 (9.7%) patient withdrawals (Figure 1) . Of the included patients, 64 (5.4%) were found not to have a pelvic mass. The remaining 1130 patients (94.6%) had a total of 1502 pelvic masses. Table 3 ). All 14 fat-containing lesions were benign.
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Among 133 women assigned a score of 5, 9 premenopausal (6.8%) and 5 menopausal women (3.8%) had benign lesions (false-positive rate, 10.5%), including 5 (35.7%) with mature teratomas, 2 (14.3%) with pelvic inflammatory disease, 2 (14.3%) with cystadenofibroma, 1 (7.1%) with Brenner tumors, 1 (7.1%) with serous cystadenoma, 1 (7.1%) with ovarian fibroma, 1 (7.1%) with struma ovarii, and 1 (7.1%) with a luteal cyst. Of the 6 fat-containing lesions, 5 (83.3%) were benign and 1 (16.7%) was a malignant germ cell (endodermal sinus) tumor ( Table 3 ). The PLR for score 2 was 0.01; for score 3, 0.27; for score 4, 4.42; and for score 5, 38.81.
Potential Consequences for Management
In the study population, 580 of 1130 women (51.3%) with a mass on MRI and no specific 
Reproducibility
The interrater agreement of the score between experienced and junior readers was substantial (κ = 0.784; 95% CI 0.743-0.824). Interrater agreement between experienced readers was also substantial (κ = 0.804; 95% CI, 0.764-0.844).
Analysis of the Criteria Used in the MRI Score at the Lesion Level
The overall prevalence of malignancy per lesion at histology was 18.4% (277 of 1502), 11.5% 
Discussion
In this multicenter prospective cohort study, we demonstrated that a previously published 14 5-point MRI score provided robust risk stratification of sonographically indeterminate adnexal masses. The study confirms a strong concordance of the PLR of malignant neoplasms for each category.
Therefore, the MRI score may provide potentially crucial information for determining the therapeutic strategy, allowing the risks and benefits of expectant management or surgery to be considered case by case. 19 The study demonstrated the feasibility of the acquisition of the multiparametric MRI in multiple centers. Substantial interrater agreement was found, regardless of reader experience, which has been reported to be challenging in some ultrasonographic studies. [20] [21] [22] External validations in smaller single-center studies have reported similar findings. [23] [24] [25] The O-RADS MRI score is now proposed as the accepted score for risk assignment of sonographically indeterminate adnexal masses, supported by this strong evidence base.
The O-RADS MRI score addresses a significant clinical issue, given that approximately 18% to 31% of adnexal lesions detected on ultrasound remain indeterminate. 3 However, performance in real-life clinical settings has been variable, potentially because of differences in operator experience and cancer prevalence in the population being studied. 27, [32] [33] [34] Correctly classifying an adnexal mass as benign has positive consequences, including the potential to reduce overtreatment by unnecessary or overextensive surgery, to allow consideration of minimally invasive or fertility-preserving surgery, and to improve patient information regarding the risk of ovarian reserve alteration after surgery. The preponderant contribution of MRI in adnexal mass evaluation is its specificity, allowing confident diagnosis of many benign adnexal lesions. 19 Using the O-RADS MRI score, our study demonstrated that, even in sonographically indeterminate masses, a lesion with a score of 2 has a PLR of malignant tumor of no greater than 0.01, and a lesion with a score of 3 has the PLR of malignant tumor of 0.27 among both experienced and junior readers. Thus, patients with lesions with scores of 2 or 3 can make an informed decision with the support of their physicians to undergo a minimally invasive or conservative surgical approach or expectant management. Such a high-performance clinical scoring system could allow for the development of decision-support tools, with referral of patients for appropriate follow-up vs surgery, and ensure that fertility-preserving treatment options are considered for young patients with early-stage disease. 35 Our study showed that the likelihood of a borderline tumor when a lesion scores 5 was very low (<6%), as in a previous publication. 14 However, as borderline tumors are a rare entity, our population included less than 3% (45 of 1502), and larger specific studies are needed.
Optimal management also relies on identifying the site of origin of a pelvic mass (ie, adnexal or nonadnexal). Our study showed that MRI helped to correctly reclassify the origin of the presumed adnexal mass on ultrasonography. In 802 women with only 1 mass described on MRI, 81 lesions 
Limitations
This study has limitations. It was observational and without randomization, and the score was not integrated into clinical decision-making. Therefore, the clinical consequences on the number of cases in which surgery can be avoided or tailored can only be imputed. However, the validation of the score now allows studies to test the consequences of the O-RADS MRI score in treatment planning; 2 such studies are currently underway. 36,37 Furthermore, because patients were managed according to clinical recommendations, when no pelvic mass was found on MRI, no specific follow-up was undertaken in clinical care as in previous base studies. 4, 5 Consequently, 64 such cases were excluded from our analysis. This is a low proportion compared with the number of resolving lesions that are typically seen in general outpatient adnexal ultrasonography, given that most physiological ovarian masses are recognized and not referred for MRI. Thus, the O-RADS MRI score estimates the risk of malignancy of an existing pelvic mass detected on MRI. Magnetic resonance imaging is not recommended as a screening tool, and as such, the NPV when no mass is found is not available in the literature. In our study, 284 women had 2 lesions and 44 women had 3 lesions. As each mass was not considered independently, a potential clustering effect should be considered. In addition, 99 of 362 patients were observed during 2 years with only clinical assessment that cannot replace imaging evaluation. Furthermore, we did not include patients who were lost to follow-up in the final analysis.
This could have biased the prevalence of the disease in the population, and that is why we calculated the PLR of malignant neoplasms and not the PPV. Of note, more than 90% of these patients were diagnosed with benign lesions on MRI, and this is likely to have played a part in the decision not to undertake further clinical follow-up.
Conclusions
In conclusion, this prospective multicenter cohort study confirmed the performance of a 5-point scoring system developed in a previous retrospective single-center study. The current study provides strong supporting evidence, and the score is now presented as the O-RADS MRI score. Using this score in clinical practice may allow a tailored, patient-centered approach for masses that are sonographically indeterminate, preventing unnecessary surgery, less extensive surgery, or fertility preservation when appropriate, while ensuring preoperative detection of lesions with a high likelihood of malignancy.
